Bayer AG - Leverkusen, Germany-based pharmaceutical company - Notes positive new data for finerenone in patients with a combination of atherosclerotic cardiovascular disease, chronic kidney disease and type 2 diabetes. Company says new data indicates that, compared to a placebo, finerenone consistently reduced the risk of cardiovascular and kidney outcomes.
"We are delighted to see that finerenone shows cardiovascular and kidney benefits in a broad range of patients with chronic kidney disease and type 2 diabetes, particularly those with atherosclerotic cardiovascular disease, who are at the highest risk of death," says Christian Rommel, head of Research & Development at Bayer.
Current stock price: EUR65.07
12-month change: up 21%
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.